vs
Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and PureCycle Technologies, Inc. (PCT). Click either name above to swap in a different company.
PureCycle Technologies, Inc. is the larger business by last-quarter revenue ($2.7M vs $2.5M, roughly 1.1× Bolt Biotherapeutics, Inc.). Bolt Biotherapeutics, Inc. runs the higher net margin — -265.2% vs -697.1%, a 431.9% gap on every dollar of revenue.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
PureCycle Technologies, Inc. is a sustainable materials firm with proprietary advanced polypropylene recycling technology. It converts contaminated polypropylene waste into high-purity virgin-equivalent resin for use in consumer goods, automotive parts, packaging and industrial products, serving global partners.
BOLT vs PCT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.5M | $2.7M |
| Net Profit | $-6.6M | $-18.8M |
| Gross Margin | — | — |
| Operating Margin | -283.4% | -2196.1% |
| Net Margin | -265.2% | -697.1% |
| Revenue YoY | — | — |
| Net Profit YoY | 58.4% | 71.0% |
| EPS (diluted) | $-9.38 | $-0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5M | $2.7M | ||
| Q3 25 | $2.2M | $2.4M | ||
| Q2 25 | $1.8M | $1.6M | ||
| Q1 25 | $1.2M | $1.6M | ||
| Q4 24 | $0 | $0 | ||
| Q3 24 | $1.1M | $0 | ||
| Q2 24 | $1.3M | $0 | ||
| Q1 24 | $5.3M | $0 |
| Q4 25 | $-6.6M | $-18.8M | ||
| Q3 25 | $-7.1M | $-28.4M | ||
| Q2 25 | $-8.6M | $-144.2M | ||
| Q1 25 | $-11.0M | $8.8M | ||
| Q4 24 | $-15.9M | $-64.7M | ||
| Q3 24 | $-15.2M | $-90.6M | ||
| Q2 24 | $-21.2M | $-48.2M | ||
| Q1 24 | $-10.8M | $-85.6M |
| Q4 25 | -283.4% | -2196.1% | ||
| Q3 25 | -355.1% | -1602.2% | ||
| Q2 25 | -510.5% | -2763.5% | ||
| Q1 25 | -991.4% | -2387.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1441.1% | — | ||
| Q2 24 | -1772.3% | — | ||
| Q1 24 | -324.1% | — |
| Q4 25 | -265.2% | -697.1% | ||
| Q3 25 | -329.4% | -1167.5% | ||
| Q2 25 | -474.6% | -8741.8% | ||
| Q1 25 | -903.4% | 559.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1330.1% | — | ||
| Q2 24 | -1662.4% | — | ||
| Q1 24 | -205.0% | — |
| Q4 25 | $-9.38 | $-0.14 | ||
| Q3 25 | $-3.72 | $-0.31 | ||
| Q2 25 | $-4.46 | $-0.81 | ||
| Q1 25 | $-0.29 | $0.05 | ||
| Q4 24 | $-13.73 | $-0.40 | ||
| Q3 24 | $-7.93 | $-0.54 | ||
| Q2 24 | $-11.12 | $-0.29 | ||
| Q1 24 | $-0.28 | $-0.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.5M | $156.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.5M | $45.9M |
| Total Assets | $56.7M | $922.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.5M | $156.7M | ||
| Q3 25 | $31.9M | $234.4M | ||
| Q2 25 | $34.8M | $284.1M | ||
| Q1 25 | $38.8M | $22.5M | ||
| Q4 24 | $47.3M | $15.7M | ||
| Q3 24 | $53.8M | $83.7M | ||
| Q2 24 | $73.7M | $10.9M | ||
| Q1 24 | $91.3M | $25.0M |
| Q4 25 | $26.5M | $45.9M | ||
| Q3 25 | $32.1M | $68.2M | ||
| Q2 25 | $38.8M | $98.9M | ||
| Q1 25 | $46.8M | $238.2M | ||
| Q4 24 | $57.2M | $180.4M | ||
| Q3 24 | $72.0M | $241.4M | ||
| Q2 24 | $85.9M | $291.6M | ||
| Q1 24 | $104.2M | $336.8M |
| Q4 25 | $56.7M | $922.7M | ||
| Q3 25 | $65.1M | $989.1M | ||
| Q2 25 | $75.5M | $1.0B | ||
| Q1 25 | $85.9M | $787.3M | ||
| Q4 24 | $99.6M | $798.4M | ||
| Q3 24 | $109.3M | $788.8M | ||
| Q2 24 | $124.2M | $719.8M | ||
| Q1 24 | $142.9M | $734.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $-28.7M |
| Free Cash FlowOCF − Capex | — | $-42.0M |
| FCF MarginFCF / Revenue | — | -1559.6% |
| Capex IntensityCapex / Revenue | — | 495.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-183.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | $-28.7M | ||
| Q3 25 | $-9.7M | $-38.5M | ||
| Q2 25 | $-9.6M | $-36.7M | ||
| Q1 25 | $-13.4M | $-38.9M | ||
| Q4 24 | $-14.4M | $-31.8M | ||
| Q3 24 | $-14.0M | $-33.4M | ||
| Q2 24 | $-16.1M | $-40.4M | ||
| Q1 24 | $-16.8M | $-39.2M |
| Q4 25 | — | $-42.0M | ||
| Q3 25 | — | $-42.4M | ||
| Q2 25 | — | $-45.3M | ||
| Q1 25 | — | $-53.9M | ||
| Q4 24 | — | $-53.4M | ||
| Q3 24 | $-14.0M | $-42.6M | ||
| Q2 24 | — | $-50.8M | ||
| Q1 24 | — | $-53.5M |
| Q4 25 | — | -1559.6% | ||
| Q3 25 | — | -1743.1% | ||
| Q2 25 | — | -2747.1% | ||
| Q1 25 | — | -3409.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1227.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 495.1% | ||
| Q3 25 | — | 160.3% | ||
| Q2 25 | — | 521.5% | ||
| Q1 25 | — | 949.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.6% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -4.40× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
